Cerebrolysin REGistry Study in Stroke

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ever Neuro Pharma GmbH
• Collaborator: SITS International
• Treatments: Cerebrolysin

Criteria

Inclusion Criteria:

• Signed informed consent

• Clinical diagnosis of acute ischemic stroke

• Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)

• Reasonable expectation of successful follow-up (max. 100 days)

Exclusion Criteria:

• none